TheraRadar
← Back
Data updated: Nov 8, 2026

BOSTON

Pharma
OncologyRespiratoryCardiovascular Execution: Fair

BOSTON is a pharmaceutical company focused on Oncology, Respiratory, Cardiovascular. Key products include VARITHENA.

2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

BOSTON at a Glance

  • Fast trial execution (32 months median completion)

BOSTON's Key Drugs

BOSTON's core commercial portfolio centers on VARITHENA, spanning Oncology and Respiratory — its most strategically important drugs approved in the last 15 years.

VARITHENA
Cardiovascular

Varicose Veins

venous endothelium Approved 2013

BOSTON's Recent FDA Approvals

New NDA/BLA approvals for BOSTON over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

BOSTON's Therapeutic Areas

BOSTON's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Respiratory, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 47%
0 drugs Phase 3: 4 Phase 2: 2 Phase 1: 5
Respiratory 21%
0 drugs Phase 3: 2 Phase 1: 3
Cardiovascular 13%
0 drugs Phase 3: 1 Phase 1: 3
Metabolic 11%
0 drugs Phase 2: 3
Neurology 8%
0 drugs Phase 2: 2

BOSTON Pipeline Snapshot

BOSTON has 25 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 7 Phase 2 and 11 Phase 1.

7
Phase 3
7
Phase 2
11
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • VARITHENA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 6/8 completed
  • • Speed: 32 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges